The HCMI involves multiple international organizations, including the National Cancer Institute (NCI), Cancer Research UK, the Wellcome Sanger Institute, and the Hubrecht Organoid Technology. These organizations work together to collect tumor samples from patients treated across different healthcare systems worldwide. The samples are then used to create next-generation cancer models, such as organoids and patient-derived xenografts, which are distributed to researchers for scientific studies.
